Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharmaceuticals

This page shows the latest Jazz Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

Jazz Pharmaceuticals ’Vyxeos (liposomal daunorubicin/cytarabine) was the fourth orphan disease drug to be recommended by the CHMP, getting the nod for the treatment of newly-diagnosed acute myeloid leukaemia (AML). ... changes in the EU, according to

Latest news

  • Novartis gets EU nod for leukaemia drug Rydapt Novartis gets EU nod for leukaemia drug Rydapt

    Jazz Pharmaceuticals got the nod for Vyxeos – a fixed -dose combination of cytarabine and daunorubicin that became the first drug in the US for newly diagnosed therapy-related AML (t-AML)

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    Jazz Pharma bags FDA approval for rare disease drug. Defitelio given the green light to treat patients who develop severe hepatic VOD. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

  • Shire drawn into Luxembourg tax haven exposé Shire drawn into Luxembourg tax haven exposé

    Other pharma companies appearing in an ICIJ database of leaked documents - related to tax rulings that have been approved by Luxembourg officials - include Abbott, Covidien, EUSA Pharma (now Jazz Pharmaceuticals), GE,

  • SMC: Celgene's Abraxane 'too expensive' for Scotland SMC: Celgene's Abraxane 'too expensive' for Scotland

    Drugs that received positive opinions included Janssen's Invokana (canagliflozin) for type 2 diabetes, Jazz Pharmaceuticals' Defitelio (defibrotide) for liver disease, GSK's respiratory combination Relvar Ellipta (fluticasone furoate / vilanterol)

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz Pharmaceuticals has agreed a $1bn deal to acquire Italy's Gentium and a recently-approved drug for a rare liver condition. ... Ireland-headquartered Jazz, which like Gentium focuses on speciality pharmaceuticals, said it expects the transaction to

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Jazz Pharmaceuticals paid $15m in upfront and option payments to Pfenex for the rights to a portfolio of early stage products in haematology/oncology. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion). Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    490. Aerial BioPharma/ Jazz Pharmaceuticals. Product rights. Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones ... 100. Cancer Prevention

  • Pharma deals during September 2012 Pharma deals during September 2012

    Dual-affinity re-targeting (DART) platform technology for cancer targets. 1, 100. Selexys Pharmaceuticals  / Novartis Pharmaceuticals. ... Jazz Pharmaceuticals / Meda. Division acquisition. Women's health division. 95. NextMed (Apricus Bio) / Takeda

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • EUSA Pharma appoints Lee Morley as its new chief executive EUSA Pharma appoints Lee Morley as its new chief executive

    Morton originally founded EUSA in 2005, leading it until its 2012 acquisition by Jazz Pharmaceuticals for $700m and then taking the reins again last month when EUSA was once again launched ... business. Prior to his time with Jazz, and before that the pre

  • EUSA Pharma founder to chair Glide Pharma EUSA Pharma founder to chair Glide Pharma

    EUSA was sold to Jazz Pharmaceuticals in 2012 for $700m. His other entrepreneurial experience in the industry includes founding Zeneus Pharma, which was acquired by Cephalon for $360m.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics